Navigation Links
Omeros Corporation Reports First Quarter 2011 Financial Results
Date:5/10/2011

tral nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.

Forward-looking StatementsThis press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding Omeros' clinical plans for OMS103HP and OMS302 and that Omeros may have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2011. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future. OMEROS CORP
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
(Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held medical ... an exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock ... system for the treatment of cancer in ... is the world,s first and only MRI-guided radiation therapy ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... in Humans and Quark,s Proprietary siRNA StructuresFREMONT, ... a development-stage pharmaceutical company discovering and developing ... that James D. Thompson, Ph.D., Vice President, ... novel pipeline of synthetic siRNA compounds at ...
... of Osteoplasty -- an Interventional Radiology Treatment -- ... March 9 Osteoplasty -- a highly effective ... of metastatic bone disease by injecting bone cement ... substantial pain relief, often presenting individuals who are ...
Cached Medicine Technology:Quark Pharmaceuticals Presents at Asia TIDES Conference 2Quark Pharmaceuticals Presents at Asia TIDES Conference 3Metastatic Bone Disease Patients Can Walk in Lazarus' Footsteps 2Metastatic Bone Disease Patients Can Walk in Lazarus' Footsteps 3Metastatic Bone Disease Patients Can Walk in Lazarus' Footsteps 4Metastatic Bone Disease Patients Can Walk in Lazarus' Footsteps 5
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list of ... . , Some types of vehicles cannot be covered under ... blog post to see if their vehicle qualifies for auto insurance ... of the cars that cannot be covered by a plan. Clients ...
(Date:12/26/2014)... December 26, 2014 The US represents the ... report. In 2013, GlobalData’s forecast estimates that sales of branded ... market due to the high incidence of the disease, high ... 5EU, Japan, and China. Increased sales of CRC therapies over ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... , BEDFORD, N.H., Oct. 1 Emerson Ecologics, ... Research as their exclusive distributor. Effective immediately, Emerson ... the complete line of Crayhon Research products. ... supplements for the brain and body, available to ...
... Oct. 1 Two interactive computer tools released today ... help emergency planners and responders select and run alternate ... experiencing a surge in seriously ill patients requiring acute ... to alternate care sites. , Alternate care ...
... Smile, a worldwide children,s medical charity, will honor Jessica, Ashlee, ... Honorable Richard J. Riordan, Roselyn Sanchez and Eric Winter at ... Beverly Hilton Hotel. Access Hollywood,s Billy Bush will ... , Operation Smile Co-founders, Dr. Bill and Kathy Magee, ...
... with certain birth defects, research shows , THURSDAY, Oct. ... likely to give birth to babies with heart defects, a ... and Prevention researchers analyzed data on 6,440 infants with congenital ... took part in the National Birth Defects Prevention Study. , ...
... presentations available through live Webcasts from Honolulu ... (ADA) interactive Education in the Round (EIR) live-patient ... the convention center to thousands of North American dental ... and the American Dental Education Association (ADEA) recently announced ...
... (MIAW) is Oct. 4-10, 2009 and as part of its observance, ... is calling attention to a program now airing on PBS, " ... Observed annually the first full week in October, Congress established MIAW ... such as major depression, bipolar disorder, and schizophrenia ...
Cached Medicine News:Health News:Crayhon Research Now Available Exclusively Through Emerson Ecologics 2Health News:New Tools Help Emergency Planners Select Alternate Care Facilities and Transfer Patients During Disasters 2Health News:Operation Smile to Honor the Simpson Family, Stephen Berman, the Honorable Richard J. Riordan, Roselyn Sanchez and Eric Winter at 8th Annual Smile Gala in Los Angeles 2Health News:Pre-Pregnancy Weight Linked to Babies' Heart Problems 2Health News:Dental Students, Faculty Gain Live Remote Access to ADA Annual Session Courses 2Health News:Dental Students, Faculty Gain Live Remote Access to ADA Annual Session Courses 3Health News:Mental Illness Awareness Week: What You Should Know, Including PBS Broadcasts, Oct. 4-10 2
Terumo's Outlook offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... INFINITI 4F, 5F, and ... catheters is ideal for ... incorporate state-of-the-art technology and ... deliver better responsiveness, optimal ...
Medicine Products: